Health News

The FDA is drafting new guidelines for testing and approving multidrug cocktails for life-threatening diseases, the Wall Street Journal reports. “Many diseases, such as AIDS, tuberculosis and cancer, require multidrug combinations. Such drug cocktails can prevent the development of drug resistance, because the microbe or cancer cell needs to undergo more mutations to escape several drugs than to escape just one. By attacking the disease in different ways, drug combinations also improve the chances of therapeutic benefit,” the newspaper reports (Schoofs, 3/18).

Read more

Filed under: Pharmacy News
Tags: AIDS, cancer, Drug, Pharmacy, Tuberculosis

Related posts

• Scientists solve 50-year-old thalidomide puzzle (0)
  Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' could lead to new treatments [...]
  
  
• Reuters Examines Chronic Disease In Developing Countries, Future Of Drug Prices (0)
  "Global health projections leave little doubt that chronic diseases are rapidly overtaking infectious diseases, such as malaria, AIDS and tuberculosis (TB), as the world's biggest killers - a shift emphasized by a recent World Health Organization (WHO) report on global health risks," Reuters writes in a story analyzing the future of drug pricing in the [...]
  
  
• Research marks new direction to treat Pneumocystis, inflammatory diseases (0)
  A drug to treat inflammation plays a surprising role reducing the level of infection caused by an opportunistic bug that is deadly for AIDS and cancer patients and others with weakened immune systems. Read more [tags] Pharmacy News [/tags]
  
  
• Phase I clinical trial results for Fentanyl Lauriad announced by BioAlliance Pharma (0)
  BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the approval from the French Drug Agency (AFSSaPS) to enter first Phase I clinical trial for Fentanyl Lauriad®. Read more [tags] Pharmacy News [/tags]
  
  
• Keeping HIV patients on ART will have long-term economic benefits, study shows (0)
  Investments to keep 3.5 million people living with HIV on antiretroviral drugs provided by programs co-financed through the Global Fund to Fight AIDS, Tuberculosis and Malaria through 2020 will cost an estimated $14.2 billion, but "the financial savings would amount to between $12 billion and $34 billion," according to a study published in the journal [...]